Funding for this research was provided by:
Vlaamse Impulsfinanciering voor Netwerken voor Dementie-onderzoek (135043)
Stichting Alzheimer Onderzoek (13007, 20170032)
Flanders Research Foundation (12Y1620N, 12I2121N, 11E6319N)
Received: 10 September 2020
Accepted: 17 November 2020
First Online: 5 December 2020
Ethics approval and consent to participate
: The Ethics Committee of University Hospitals Leuven approved all study procedures (UZ Leuven reference numbers S51125 and S55892), and written informed consent was obtained from all participants.
: Not applicable
: S. De Meyer, J. Schaeverbeke, K. Poesen, B. Gille, M. De Schaepdryver, E. Luckett, S. Gabel and R. Bruffaerts declare that they have no competing interests.I. Verberk, E. Thijssen and C. Teunissen developed the SIMOA Amyblood assays in cooperation with ADx NeuroSciences.K. Mauroo is a full-time paid employee of ADx NeuroSciences.E. Stoops is a full-time paid employee and shareholder of ADx NeuroSciences.H. Vanderstichele is a co-founder of ADx NeuroSciences and a founder of Biomarkable.R. Vandenberghe was the PI of the phase 1 and 2 clinical trials with [<sup>18</sup>F]flutemetamol, and his institution has clinical trial agreements (with RV as PI) with Novartis, Roche and AbbVie.